Barely Significant
← all excerpts

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Oncotarget · 2016 · PMC4941256 · PMID 26909860

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
Generation 0 cells showed a trend toward a stronger G 1 delay in the short term, confirmed in all treatment groups, and increased delays/block in S and G 2 M in the long term, which may counteract the cell death expected after removal of gemcitabine.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.